Vanguard Group Inc Graphite Bio, Inc. Transaction History

Vanguard Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.24 - $2.66 $92,991 - $110,427	41,514 Added 3.0%	1,425,980 $3.74 Million
Q3 2023 Nov 14, 2023	BUY	$2.18 - $2.77 $10,516 - $13,362	4,824 Added 0.35%	1,384,466 $3.43 Million
Q2 2023 Aug 14, 2023	BUY	$2.47 - $3.38 $358,653 - $490,789	145,204 Added 11.76%	1,379,642 $3.59 Million
Q1 2023 May 15, 2023	BUY	$1.85 - $3.21 $13,915 - $24,145	7,522 Added 0.61%	1,234,438 $3.02 Million
Q4 2022 Feb 10, 2023	BUY	$2.82 - $3.59 $75,107 - $95,616	26,634 Added 2.22%	1,226,916 $4.07 Million
Q3 2022 Nov 14, 2022	BUY	$2.82 - $4.24 $384,566 - $578,213	136,371 Added 12.82%	1,200,282 $3.81 Million
Q2 2022 Aug 12, 2022	SELL	$2.14 - $5.23 $297,126 - $726,154	-138,844 Reduced 11.54%	1,063,911 $2.93 Million
Q1 2022 May 13, 2022	BUY	$5.1 - $13.06 $2.56 Million - $6.56 Million	502,381 Added 71.73%	1,202,755 $6.14 Million
Q4 2021 Feb 14, 2022	BUY	$8.41 - $16.71 $33,160 - $65,887	3,943 Added 0.57%	700,374 $8.71 Million
Q3 2021 Nov 12, 2021	BUY	$15.81 - $28.39 $10.5 Million - $18.9 Million	666,431 Added 2221.44%	696,431 $11.4 Million
Q2 2021 Aug 13, 2021	BUY	$18.5 - $30.73 $555,000 - $921,900	30,000 New	30,000 $921,000

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.